Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Salmeterol Xinafoate (GR 33343X xinafoate) 是选择性人β2肾上腺素受体激动剂。Salmeterol 有效刺激 cAMP 积累,能够作用于 CHO 细胞,对人β2,β1和β3肾上腺素受体的 pEC50分别为 9.6、6.1 和 5.9。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 183 | 现货 | ||
5 mg | ¥ 397 | 现货 | ||
10 mg | ¥ 672 | 现货 | ||
25 mg | ¥ 1,330 | 现货 | ||
50 mg | ¥ 2,170 | 现货 | ||
100 mg | ¥ 3,670 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 543 | 现货 |
产品描述 | Salmeterol Xinafoate (GR 33343X xinafoate) is a long-acting β2-adrenergic receptor agonist with anti-inflammatory effects, used in the treatment of asthma symptoms and chronic obstructive pulmonary disease (COPD) symptoms. |
靶点活性 | β2-adrenoceptor (WT):Ki:1.5 nM |
体外活性 | Salmeterol significantly inhibits production of pro-inflammatory mediators by RAW264.7 and THP-1 cells. Salmeterol downregulates PgLPS-mediated phosphorylation of the ERK1/2 and JNK but not p38 MAP kinases (MAP-K). Salmeterol also attenuates the activation of NF-κB via inhibition of nuclear translocation of p65-NFκB, the transcriptional activity of NF-κB and IκBα phosphorylation. Salmeterol shows very high selectivity for the WT β2AR (β1 Ki /β2 Ki ratio of approximately 1500) with Ki of 1.5±0.4 nM. Salmeterol prevents phosphorylation levels of IRS-1Ser307 induced by tumor necrosis factor-α. Salmeterol alone prevents cell death in retinal Müller cells (p<0.05 versus 25 mM glucose). Salmeterol in conbination with IRS-1 shRNA shows a significant increase in cell death compared to salmeterol alone. Moreover, salmeterol alone treatment significantly reduces cytochrome C levels, with the effect lessened when salmeterol is combined with IRS-1 shRNA. Salmeterol (100 μM) causes apoptosis of DCs, and can not affect the differentiation and maturation of DCs at 10 μM. Salmeterol (10 μM) decreases the mRNA and protein levels of pro-inflammatory cytokines in LPS-activated DCs and inhibits MAPK and NF-κB activation |
体内活性 | The OVA/LPS groups with salmeterol result in a significant decrease in the enhanced AHR in allergic mice in a dose-dependent manner. Salmeterol contends with asthma via regulating the inflammation of the airway of the mice. |
激酶实验 | The cells are rinsed twice with ice-cold phosphate-buffered saline and mechanically detached in ice-cold buffer containing 10 mM Tris·HCl, pH 7.4, 5 mM EDTA, 10 μg/mL benzamidine, 10 μg/mL soybean trypsin inhibitor (type II-S), and 5 μg/mL leupeptin (lysis buffer). The lysate is centrifuged at 45,000 ×g for 10 min at 4°C. The pellet is rehomogenized in lysis buffer, with a Potter-type homogenizer, and stored at ?80°C until use. The competition binding assays are performed in buffer containing 75 mM Tris·HCl, pH 7.4, 12.5 mM MgCl2, and 2 mM EDTA, using 1-5 μg of membrane protein, 50 pM 125I-CYP, and 0-100 μM unlabeled ligand in the presence of 100 μM GTP, for 60 min at 37°C. The binding reaction is terminated by dilution and rapid filtration through Whatman GF/C filters; the filters are washed three times with solution containing 25 mM Tris·HCl, pH 7.4, and 1 mM MgCl2. Nonspecific binding is determined in the presence of 5 μM (±)-propranolol. The radioactivity on the filters is counted with a γ-counte |
动物实验 | Salmeterol is formulated in PBS.All mice are sensitized on days 0 and 14 by intraperitoneal injection of either PBS or 0.08 mg OVA and 0.1 mL aluminum hydroxide in 0.1 mL of PBS (pH 7.4). After sensitization, animals are exposed to aerosolized PBS-only (negative control), 1% OVS/PBS (acute exposure), 1% OVA/0.01% LPS/PBS (extra LPS exposure) or 1% OVA/0.01% LPS/salmeterol/PBS (sal treatment) for 40 min, once per day for 3 consecutive days (days 24-26). On day 27, the mice are killed and lungs are divided into two groups for analysis: the left lung lobes are lavaged three times with 1 mL of PBS with 1% fetal calf serum and 5 U/mL heparin, and the right halves are fixed by 4% paraformaldehyde for histological analysis. |
别名 | Salmetedur, 昔美酸沙美特罗, 沙美特罗昔萘酸酯, GR 33343X xinafoate, Arial |
分子量 | 603.75 |
分子式 | C36H45NO7 |
CAS No. | 94749-08-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 12.1 mg/mL (20 mM)
DMSO: 60.4 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 1.6563 mL | 8.2816 mL | 16.5631 mL | 41.4079 mL |
5 mM | 0.3313 mL | 1.6563 mL | 3.3126 mL | 8.2816 mL | |
10 mM | 0.1656 mL | 0.8282 mL | 1.6563 mL | 4.1408 mL | |
20 mM | 0.0828 mL | 0.4141 mL | 0.8282 mL | 2.0704 mL | |
DMSO | 50 mM | 0.0331 mL | 0.1656 mL | 0.3313 mL | 0.8282 mL |
100 mM | 0.0166 mL | 0.0828 mL | 0.1656 mL | 0.4141 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Salmeterol Xinafoate 94749-08-3 GPCR/G Protein Microbiology/Virology Neuroscience Proteases/Proteasome HIV Protease Adrenergic Receptor corticosteroid Salmetedur 昔美酸沙美特罗 Salmeterol 沙美特罗昔萘酸酯 Beta Receptor therapy inhibit GR 33343X xinafoate GR 33343X Arial combination agonist inflammatory Inhibitor inhibitor